MRNA · Moderna, Inc.
Is MRNA setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Moderna, Inc., in one place.
Today's breakout radarIs MRNA setting up for a breakout?
Breakout Radar API →Not today. MRNA is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about MRNA?
Stock Sentiment API →Bulls: Moderna's melanoma vaccine with Merck's Keytruda lowered the risk of the cancer coming back or death by 42% in Phase 3, and CEO Stéphane Bancel said the clinical impact is 'real and big' and that the vaccine will work in more cancers, with lung and pancreas data still ahead. Piper raised its price target to $230 from $167. The stock rallied almost 70% in a few weeks, held $182.55 support and ran 14% off it, and on one session gapped down 3.49% to $191.92 before bulls filled the entire gap to close at $207.74 — a gap-down of that size has filled only 22% of the time historically.
Bears: The 42% recurrence-risk reduction was not enough: the data leaked early after a big run-up, and $MRNA fell about 17% on the news, then 9% and 7% to $185.74 as the distant-spread results came in far smaller than the earlier study showed — while $IBB rose 0.2% and $SPY 0.3%. William Blair downgraded the stock from Outperform to Market Perform, and bears flag $180 as the critical level, with a break pointing to $130, and $200 still rejecting.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about MRNA?
News Sentiment API →No recent news reading for MRNA. The News Sentiment API reads today's headlines on any US stock.
Are MRNA insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Hoge Stephen$8.6M · Oct 15, 2026
- Sold · Hoge Stephen$96K · Oct 14, 2026
- Sold · Hoge Stephen$8.3M · Oct 14, 2026
- Sold · Hoge Stephen$5.9M · Sep 15, 2026
- Sold · Hoge Stephen$5.8M · Sep 14, 2026
How is Moderna, Inc.'s business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $145.0M | +2% | −$782.0M | $-1.97 |
| Mar 31, 2026 | $389.0M | +260% | −$1.3B | $-3.40 |
| Sep 30, 2025 | $1.0B | -45% | −$200.0M | $-0.51 |
| Jun 30, 2025 | $142.0M | -41% | −$825.0M | $-2.13 |
From the company's SEC filings (10-Q and 10-K).
What does Moderna, Inc. expect?
Company Guidance API →- 2026 · revenue growth · 8-K filed Jul 31, 2026
“Reiterates plan to deliver up to 10% revenue growth in 2026”
- 2026 · cost of sales · 8-K filed Jul 31, 2026
“Cost of sales for 2026 is expected to be approximately $1.7 billion, lowered from approximately $1.8 billion, and including the $0.9 billion non-recurring litigation settlement charge.”
- 2026 · research and development expenses · 8-K filed Jul 31, 2026
“Research and development expenses for 2026 are now anticipated to be approximately $2.9 billion, lowered from approximately $3.0 billion.”
- 2026 · selling, general and administrative expenses · 8-K filed Jul 31, 2026
“Selling, general and administrative expenses for 2026 are projected to be approximately $1.0 billion.”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.